THE EFFECTS OF ERDOSTEINE ON COAGULATION IN RATS

Motor S., Alp H., Yuksel R., Erden E. S., OKTAR S., Celik S., ...Daha Fazla

ACTA MEDICA MEDITERRANEA, cilt.30, sa.4, ss.801-804, 2014 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 30 Sayı: 4
  • Basım Tarihi: 2014
  • Dergi Adı: ACTA MEDICA MEDITERRANEA
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.801-804
  • Anahtar Kelimeler: erdosteine, coagulation, antithrombin III, factor VIII, factor IX, protrombin time (PT), activated partial tromboplastin time (aPTT), international normalized ratio (INR), protein C and S, N-ACETYLCYSTEINE, PROTHROMBIN TIME, PLASMA SAMPLES, IN-VITRO
  • Akdeniz Üniversitesi Adresli: Evet

Özet

Background and objectives: Erdosteine, a thiol derivative in the same group as N-acetyl cysteine, belongs to a class of medicines called expectorants.

Background and objectives

: Erdosteine, a thiol derivative in the same group as N-acetyl cysteine, belongs to a class of medicines

called expectorants.

Aim

: It was aimed to determine effects of erdosteine (ERD) on coagulation.

Material and methods

: A total of 23 female rats were divided into three groups as control (C) (n=7), ERD-10 (n=7), ERD-50

(n=9). Rats in C group were given dilution of 0.3 ml sodium bicarbonate [NaHCO3]; rats in ERD-10 group were given 10 mg/kg

ERD; and rats in ERD-50 group were given 50 mg/kg ERD. The drugs were given for ten days by oral gavage. Blood samples were

drawn from the heart 24 hours after the last drug dose, and coagulation parameters were measured with automated analyzers.

Results: While Factor VIII and AT-III levels decreased in both ERD-10 and ERD-50 group, Factor IX levels only decreased in

ERD-50 group. Also, INR, PT and aPTT were prolonged in the ERD-50 group compared with the control and ERD-10 groups. There

was no significant difference between groups for protein C and S.

Conclusion

: The results showed that erdosteine may increase bleeding tendencies in a dose-related manner. Therefore, we suggest

that it should be noted when erdosteine is used together with anticoagulant medications. In addition, patients should be questioned

regarding the use of erdosteine before dental or medical operations in order to prevent bleeding abnormalities.